Production and radiochemical purity of 177Lu-PSMA-617 for clinical trial

被引：0
|
作者：
Asad, Ali [1 ]
Scharli, Rainer [2 ]
Morandeau, Laurence [1 ]
Price, Roger [3 ]
机构：
[1] Sir Charles Gairdner Hosp, Nedlands, WA, Australia
[2] Univ Western Australia, Nedlands, WA, Australia
[3] Sir Charles Gairdner Hosp, Med Technol & Phys, Nedlands, WA, Australia
来源：
JOURNAL OF LABELLED COMPOUNDS & RADIOPHARMACEUTICALS | 2019年 / 62卷
关键词：
D O I：
暂无
中图分类号：
Q5 [生物化学];
学科分类号：
071010 ; 081704 ;
摘要：
P-358
引用
收藏
页码：S527 / S527
页数：1
相关论文
共 50 条
  • [31] 177Lu-PSMA-617 radioligand therapy of mCRPC: evaluation criteria of response
    Kambiz Rahbar
    Martin Bögemann
    Hojjat Ahmadzadehfar
    European Journal of Nuclear Medicine and Molecular Imaging, 2017, 44 : 166 - 167
  • [32] Initial Experience with 177Lu-PSMA-617 Therapy: Toxicity and Outcomes PostApproval
    Tuchayi, Abuzar Moradi
    Kim, Sarasa
    Morley, Amanda
    Saelee, Rachelle
    Wang, Yingbing
    Heath, Courtney Lawhn
    Juarez, Roxanna
    Hope, Thomas
    JOURNAL OF NUCLEAR MEDICINE, 2023, 64
  • [33] Production, quality control, biodistribution and imaging studies of 177Lu-PSMA-617 in breast adenocarcinoma model
    Sharifi, Mehdi
    Jalilian, Amir Reza
    Yousefnia, Hassan
    Alirezapour, Behrouz
    Bahrami-Samani, Ali
    Zolghadri, Samaneh
    RADIOCHIMICA ACTA, 2018, 106 (06) : 507 - 513
  • [34] Clinical implementation of 177Lu-PSMA-617 (LuPSMA) at a major academic center: Initial experiences.
    Ravi, Praful
    Kelly, Emma
    Whelpley, Bridget
    Choudhury, Atish Dipankar
    Sunkara, Rajitha
    Pomerantz, Mark
    Taplin, Mary-Ellen
    Kilbridge, Kerry L.
    Wei, Xiao X.
    Morgans, Alicia K.
    Bizzo, Renata Rocha de Almeida
    Wolanski, Andrew
    Jacene, Heather
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41
  • [35] Quantitative assessment of PSMA imaging before and after 177Lu-PSMA-617 treatment in a Ph I/II trial.
    Nauseef, Jones T.
    Thomas, Charlene
    Sun, Michael
    Sartor, A. Oliver
    Singh, Sharon
    Bissassar, Mahelia
    Fernandez, Escarleth
    Tan, Angela
    Patel, Amie
    Zuloaga, Juana Martinez
    Naiz, Muhammad Obaid
    Imad, Dunya
    Vallabhajosula, Shankar
    Molina, Ana M.
    Sternberg, Cora N.
    Nanus, David M.
    Osborne, Joseph
    Bander, Neil Harrison
    Perk, Tim
    Tagawa, Scott T.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (06)
  • [36] Activity of 177Lu-PSMA-617 in Patients With Advanced Prostate Cancer and Brain Metastases
    Rashid, Narmeen S.
    Rami, Avina
    Lang, Min
    Stoltenberg, Hailey
    Wolanski, Andrew
    Ritzer, Jolivette
    Jacene, Heather
    Ravi, Praful
    CLINICAL GENITOURINARY CANCER, 2025, 23 (02)
  • [37] 177Lu-PSMA-617 radioligand therapy of mCRPC: evaluation criteria of response Reply
    Yadav, Madhav Prasad
    Ballal, Sanjana
    Tripathi, Madhavi
    Bal, Chandrasekhal
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2017, 44 (01) : 168 - 169
  • [38] Experimental 177Lu-PSMA-617 radioligand therapy in a patient with extended metastasized leiomyosarcoma
    Jueptner, Michael
    Marx, Marlies
    Zuhayra, Maaz
    Luetzen, Ulf
    NUKLEARMEDIZIN-NUCLEAR MEDICINE, 2019, 58 (04): : 328 - 330
  • [39] In vitro vitro response of 177Lu-PSMA-617 with two different specific activities
    Villas Boas, Cristian Wieczorek
    Mengatti, Jair
    Passos, Priscila
    Vieira, Daniel
    de Araujo, Elaine Bortoleti
    JOURNAL OF NUCLEAR MEDICINE, 2020, 61
  • [40] Myelotoxicity after Treatment with 177Lu-PSMA-617 in Patients with Metastatic Prostate Cancer
    Groener, D.
    Baumgarten, J.
    Davis, K.
    Happel, C.
    Mader, N.
    Ngoc, C. Nguyen
    Wichert, J.
    Mandel, P.
    Tselis, N.
    Gruenwald, F.
    Sabet, A.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2020, 47 (SUPPL 1) : S694 - S695
12345